Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Completed · Phase 3 · NCT05255991
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
At a glance
- Research payments reported, 2025
- $9,326
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 597
About the trial
- Sponsor
- United Therapeutics
- Tested
- Placebo (drug), Inhaled Treprostinil (drug), Treprostinil Ultrasonic Nebulizer (device)
- Dates
- Started 2022-09-12; completion 2025-06-30
- Results posted
- Yes
Study RIN-PF-303 is a multinational study designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
From ClinicalTrials.gov, last updated 2026-10-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
United Therapeutics Corporation reported $9,326 in research payments for this study in 2025 (4 payments).
Products named: Tyvaso
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $9,326
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.